Index/Topics/Presidential Cognitive Screenings

Presidential Cognitive Screenings

The use of cognitive screenings, specifically the Montreal Cognitive Assessment, in evaluating the mental fitness of presidents.

Fact-Checks

6 results
Jan 27, 2026
Most Viewed

How strong is the evidence that Donald Trump has dementia?

The publicly available evidence that has dementia is mixed and circumstantial: multiple clinicians and commentators point to changes in gait, speech, memory lapses and impulsivity as worrisome signs, ...

Jan 17, 2026
Most Viewed

What public evidence exists about Donald Trump’s cognitive assessments and medical disclosures?

Public evidence about Donald Trump’s cognitive assessments comprises a small set of official disclosures and media reporting: a 2018 Montreal Cognitive Assessment (MoCA) reportedly scored 30/30 (annou...

Jan 16, 2026
Most Viewed

How do the Montreal Cognitive Assessment (MoCA) and standard IQ tests differ in purpose and interpretation?

The Montreal Cognitive Assessment (MoCA) is a brief, multidomain cognitive screen designed to detect mild cognitive impairment and early dementia in clinical settings, with emphasis on attention and e...

Jan 14, 2026

What publicly available medical information exists about presidential cognitive screenings and how are they interpreted by clinicians?

Publicly available medical information about presidential cognitive screenings centers largely on the Montreal Cognitive Assessment (MoCA), a 10–15 minute, 30-point screening tool designed to detect m...

Jan 29, 2026

How reliable are short cognitive tests like the MoCA for detecting presidential‑level cognitive decline?

Short cognitive screens such as the are well‑validated, rapid tools that are sensitive to early, mild and widely used as first‑line screens . However, they are not diagnostic instruments and—when used...

Feb 3, 2026

How reliable is the Montreal Cognitive Assessment (MoCA) in one-off public administrations for detecting early dementia?

) is a well-validated, brief instrument that is more sensitive than for detecting and early Alzheimer’s-type changes, but its performance in single, one-off public screening campaigns is constrained b...